1. Cell Cycle/DNA Damage
  2. DNA/RNA Synthesis

DNA/RNA Synthesis

RNA synthesis, which is also called DNA transcription, is a highly selective process. Transcription by RNA polymerase II extends beyond RNA synthesis, towards a more active role in mRNA maturation, surveillance and export to the cytoplasm.

Single-strand breaks are repaired by DNA ligase using the complementary strand of the double helix as a template, with DNA ligase creating the final phosphodiester bond to fully repair the DNA.DNA ligases discriminate against substrates containing RNA strands or mismatched base pairs at positions near the ends of the nickedDNA. Bleomycin (BLM) exerts its genotoxicity by generating free radicals, whichattack C-4′ in the deoxyribose backbone of DNA, leading to opening of the ribose ring and strand breakage; it is an S-independentradiomimetic agent that causes double-strand breaks in DNA.

First strand cDNA is synthesized using random hexamer primers and M-MuLV Reverse Transcriptase (RNase H). Second strand cDNA synthesis is subsequently performed using DNA Polymerase I and RNase H. The remaining overhangs are converted into blunt ends using exonuclease/polymerase activity. After adenylation of the 3′ ends of DNA fragments, NEBNext Adaptor with hairpin loop structure is ligated to prepare the samples for hybridization. Cell cycle and DNA replication are the top two pathways regulated by BET bromodomain inhibition. Cycloheximide blocks the translation of mRNA to protein.

DNA/RNA Synthesis Related Products (56):

Cat. No. Product Name Effect Purity
  • HY-12320
    Cycloheximide Inhibitor 99.45%
    Cycloheximide (Naramycin A) is an eukaryote protein synthesis inhibitor, with IC50s of 532.5 nM and 2880 nM for protein synthesis and RNA synthesis in vivo, respectively.
  • HY-17559
    Actinomycin D Inhibitor 99.89%
    Actinomycin D inhibits DNA repair with an IC50 of 0.42 μM.
  • HY-13316
    Mitomycin C Inhibitor 98.89%
    Mitomycin C is an antitumor drug and antibiotic that shows extraordinary ability to inhibit DNA synthesis.
  • HY-17026
    Gemcitabine Inhibitor 99.80%
    Gemcitabine (NSC 613327;LY188011) is a DNA synthesis inhibitor which inhibits the growth of BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM, respectively.
  • HY-19610
    alpha-Amanitin Inhibitor 99.79%
    alpha-Amanitin is the principal toxin of several deadly poisonous mushrooms, exerting its toxic function by inhibiting RNA-polymerase II.
  • HY-13753
    Streptozocin Inhibitor 99.58%
    Streptozocin is a potent DNA-methylating agent, with IC50s of 11.7, 904 and 1024 μg/mL in HL60, K562 and C1498 cells respectively.
  • HY-17565
    Bleomycin sulfate Inhibitor >98.0%
    Bleomycin sulfate is a DNA synthesis inhibitor with potent antitumor activity.
  • HY-B0003
    Gemcitabine Hydrochloride Inhibitor 99.93%
    Gemcitabine hydrochloride is a DNA synthesis inhibitor with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM in BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells, respectively.
  • HY-18982
    Anisomycin Inhibitor 98.03%
    Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.
  • HY-17393
    Carboplatin Inhibitor 99.88%
    Carboplatin is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death. Carboplatin is a derivative of cisplatin and a potent anti-cancer agent.
  • HY-12742
    SCR7 Inhibitor 99.75%
    SCR7 is a DNA Ligase IV inhibitor with anticancer activity.
  • HY-13323
    CX-5461 Inhibitor 98.47%
    CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC50s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively.
  • HY-B0016
    Capecitabine Inhibitor 99.97%
    Capecitabine is an oral prodrug that is converted to its active metabolite, fluorouracil (FU), by thymidine phosphorylase.
  • HY-19620
    LMI070 Agonist 98.78%
    LMI070 (Branaplam) is a highly potent, selective and orally active small molecule SMN2 splicing modulator.
  • HY-19931
    COH29 Inhibitor 98.04%
    COH29 is a potent ribonucleotide reductase (RNR) inhibitor with anticancer activity. COH29 inhibits α and β subunit of RNR with IC50s of 16 μM.
  • HY-B0313
    Hydroxyurea Inhibitor >98.0%
    Hydroxyurea is a cell apoptosis inducer that inhibitDNA synthesis through inhibition of ribonucleotide reductase.
  • HY-15457
    Triciribine Inhibitor 99.20%
    Triciribine is a DNA synthesis inhibitor, also inhibits Akt and HIV-1/2 with IC50 of 130 nM, and 0.02-0.46 μM, respectively.
  • HY-16637
    Folic acid 99.56%
  • HY-101792
    RG7800 Modulator 99.86%
    RG7800 a small molecule SMN2 splicing modifier to enter human clinical trials to treat spinal muscular atrophy.
  • HY-12342
    ML216 Inhibitor
    ML216(CID-49852229) is a potent inhibitor of the DNA unwinding activity of BLM helicase; showing similar IC50s of 3.0 and 0.97 μM for full length BLM and BLM636–1298 respectively.
Isoform Specific Products

Your Search Returned No Results.


Please try each isoform separately.